Research map: Immunotherapy Rechallenge in HCC : A Second Chance for Response?

Back to the article

Papers in this map

  1. Molecular and cellular insights into T cell exhaustion · E. John Wherry · 2015 · 4756 citations · Cited by this paper
  2. Enhanced Liver Fibrosis Test, FIB ‐4 and FibroScan : Real‐World Prognostic Accuracy for MASLD in a Biopsy‐Controlled Cohort · 2026 · Related
  3. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy · Spencer C. Wei · 2018 · 3165 citations · Cited by this paper
  4. Threshold‐Defined Liver Stiffness Trajectories and Liver‐Related Event Risk in Chronic Liver Disease: A Cohort Study · 2026 · Related
  5. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma · Ann‐Lii Cheng · 2021 · 1752 citations · Cited by this paper
  6. Lactulose for Preventing Overt Hepatic Encephalopathy: Between Evidence and Unresolved Questions · 2026 · Related
  7. β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma · Marina Ruiz de Galarreta · 2019 · 937 citations · Cited by this paper
  8. Laparoscopic or Open Liver Resection Versus Multibipolar Radiofrequency Ablation of HCC Within Milan Criteria on Cirrhosis · 2026 · Related
  9. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma · Andrew Xiuxuan Zhu · 2022 · 666 citations · Cited by this paper
  10. Neurofilament Light Chain in Cerebrospinal Fluid and Blood Identifies Patients With Minimal and Overt Hepatic Encephalopathy · 2026 · Related
  11. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients · Emanuela Romano · 2015 · 604 citations · Cited by this paper
  12. Microtubule‐Targeting Drugs Induce Mesenchymal–Epithelial Transition in Hepatic Stellate Cells · 2026 · Related
  13. TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype · Fan Zhang · 2016 · 596 citations · Cited by this paper
  14. Burden and Regional Disparities of MASH ‐Related Liver Cancer in the Asia‐Pacific Region From 1990 to 2023 · 2026 · Related
  15. A Role for TGF-β in the Generation and Expansion of CD4+CD25+ Regulatory T Cells from Human Peripheral Blood · Satoshi Yamagiwa · 2001 · 540 citations · Cited by this paper
  16. High Rates of Advanced Chronic Liver Disease in Patients With Chronic Hepatitis D Virus Infection in Uzbekistan · 2026 · Related
  17. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies · Ryan Joseph Sullivan · 2021 · 295 citations · Cited by this paper
  18. Preoperative MRI Intratumoral Heterogeneity Radiomics for Microvascular Invasion and Recurrence‐Free Survival in HCC · 2026 · Related
  19. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification · Carla Montironi · 2022 · 254 citations · Cited by this paper
  20. Autophagy in MASLD : A Metabolic and Precision Medicine Perspective · 2026 · Related
  21. Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC · Roser Pinyol · 2019 · 253 citations · Cited by this paper
  22. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study · Changhoon Yoo · 2021 · 123 citations · Cited by this paper
  23. Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study · David James Pinato · 2019 · 122 citations · Cited by this paper
  24. Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma · Sarah Cappuyns · 2024 · 63 citations · Cited by this paper
  25. Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment · Stephen Lam Chan · 2024 · 61 citations · Cited by this paper
  26. Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma · Laia Bassaganyas · 2020 · 58 citations · Cited by this paper
  27. Myeloid‑derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma · Takahiro Tomiyama · 2022 · 33 citations · Cited by this paper
  28. Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting · Manon Falette-Puisieux · 2023 · 24 citations · Cited by this paper
  29. Hallmarks of liver cancer: Therapeutic implications · Josep Maria Llovet · 2026 · 12 citations · Cited by this paper
  30. Immune-Related Adverse Events Are Associated With Improved Outcomes After Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis · Soo Young Hwang · 2025 · 11 citations · Cited by this paper
  31. Meta‐Analysis: Immune‐Related Adverse Events Are Associated With Improved Effectiveness of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma · Shijia Liu · 2025 · 7 citations · Cited by this paper
  32. Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC : An International Multicentre Study · J -H Kim · 2025 · 7 citations · Cited by this paper
  33. Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial) · Marco Sanduzzi‐Zamparelli · 2026 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)